Arsenic in India's water could cause resistance to visceral leishmaniasis treatment

October 29, 2013 by Marcia Malory, Medical Xpress report
Leishmaniasis ulcer on left forearm. Credit: Layne Harris / Wikipedia

(Medical Xpress)—Every year, visceral leishmaniasis infects about 500,000 people and kills about 41,000. Most deaths occur in India's Bihar region, where there is a high level of resistance to the antimony compounds used to treat this parasitic tropical disease. Alan Fairlamb and his colleagues at the University of Dundee have found that arsenic contamination of Bihar's water supply could be causing resistance to antimonial treatments. Their research appears in the Proceedings of the National Academy of Sciences.

The protozoa Leishmania donovani and Leishmania infantum cause by infecting the liver, spleen and bone marrow. Victims of the disease experience fever, anorexia, weight loss and inflammation of the liver and spleen. They will die without treatment. The only drugs that can kill the parasites that cause visceral leishmaniasis are antimonial preparations, amphotericin B, miltefosine, and paromomycin.

Doctors have been using antimonial drugs to treat visceral leishmaniasis successfully in sub-Saharan Africa and South America for almost 100 years. However, in Bihar, where most instances of the disease occur, cure rates using antimonial treatments had decreased to less than 50 percent by the end of the 20th century. Because of this, antimonial drugs are no longer the recommended treatment in India.

In the 1970s, engineers installed shallow tube wells in India to provide the population with clean . Subsequently, scientists discovered these wells exposed Biharis to arsenic by transferring naturally occurring arsenic in Bihar's groundwater to the domestic water supply. Fairlamb and his team thought arsenic in Bihar's domestic water supply could be causing to antimonial treatments for visceral leishmaniasis. Arsenic and antimony share similar chemical properties, and Bihar is the only region in the world where arsenic contaminates the drinking water, visceral leishmaniasis is endemic and there is widespread resistance to antimonial medicines.

To test their hypothesis, the researchers exposed mice to water laced with arsenic until the proportion of arsenic in the tissues of the mice was similar to that found in arsenic-exposed humans. They then infected the mice with Leishmania donovani. After a month, they euthanized the mice, recovered the parasites and then infected another group of -exposed mice. They repeated this process until the parasites had infected five groups of mice. With each successive group of , the Leishmania donovani became less sensitive to the antimonial drug Pentostam. By the time they had infected the final group, the parasites had become completely resistant to the drug.

Fairlamb and his team say their research reveals an urgent need for alternative sources of domestic water in India.

Explore further: Leishmania parasites with greater infectivity associated with treatment failure

More information: Chronic exposure to arsenic in drinking water can lead to resistance to antimonial drugs in a mouse model of visceral leishmaniasis, PNAS, Published online before print October 28, 2013, DOI: 10.1073/pnas.1311535110

Abstract
The Indian subcontinent is the only region where arsenic contamination of drinking water coexists with widespread resistance to antimonial drugs that are used to treat the parasitic disease visceral leishmaniasis. We have previously proposed that selection for parasite resistance within visceral leishmaniasis patients who have been exposed to trivalent arsenic results in cross-resistance to the related metalloid antimony, present in the pentavalent state as a complex in drugs such as sodium stibogluconate (Pentostam) and meglumine antimonate (Glucantime). To test this hypothesis, Leishmania donovani was serially passaged in mice exposed to arsenic in drinking water at environmentally relevant levels (10 or 100 ppm). Arsenic accumulation in organs and other tissues was proportional to the level of exposure and similar to that previously reported in human liver biopsies. After five monthly passages in mice exposed to arsenic, isolated parasites were found to be completely refractory to 500 μg⋅mL−1 Pentostam compared with the control passage group (38.5 μg⋅mL−1) cultured in vitro in mouse peritoneal macrophages. Reassessment of resistant parasites following further passage for 4 mo in mice without arsenic exposure showed that resistance was stable. Treatment of infected mice with Pentostam confirmed that resistance observed in vitro also occurred in vivo. We conclude that arsenic contamination may have played a significant role in the development of Leishmania antimonial resistance in Bihar because inadequate treatment with antimonial drugs is not exclusive to India, whereas widespread antimonial resistance is.

Related Stories

Leishmania parasites with greater infectivity associated with treatment failure

October 8, 2013
Relapses after treatment for Leishmania infection may be due to a greater infectivity of the parasite rather than drug resistance, as has been previously thought, according to a study published in mBio, the online open-access ...

Combination therapies are a cost-effective alternative when treating visceral leishmaniasis

September 16, 2013
Visceral leishmaniasis is the second-deadliest parasitic disease after malaria. Each year, thousands fall victim among poor and marginalised populations in low-income countries. Filip Meheus is the first to detail the economic ...

Kala-azar treatment failing in Nepal

March 1, 2013
In a recent study, scientists have concluded that the cure rates of Miltefosine, the only oral drug for visceral leishmaniasis available, have significantly decreased. Miltefosine was introduced in the Indian subcontinent ...

Human neutrophil peptide-1: A new anti-leishmanial drug candidate

October 17, 2013
Leishmaniasis is a vector borne disease caused by different Leishmania species with different clinical manifestations. Cutaneous leishmaniasis (CL) is endemic and widespread especially among young individuals in Iran. Currently ...

Old drug shows new promise to treat leishmaniasis

February 2, 2012
(Medical Xpress) -- A study published yesterday shows that a drug called fexinidazole could potentially be used to treat visceral leishmaniasis, a parasitic disease that kills 50 000 to 60 000 people a year in Africa, ...

Recommended for you

Tibetan sheep highly susceptible to human plague, originates from marmots

August 16, 2018
In the Qinghai-Tibet plateau, one of the region's highest risk areas for human plague, Himalayan marmots are the primary carriers of the infectious bacterium Y. pestis. Y. pestis infection can be transmitted to humans and ...

Autoimmunity plays role in development of COPD, study finds

August 16, 2018
Autoimmunity plays a role in the development of chronic obstructive pulmonary disease (COPD), according to a study led by Georgia State University and Vanderbilt University Medical Center that analyzed human genome information ...

Reliable point-of-care blood test can help prevent toxoplasmosis

August 16, 2018
A recent study, performed in Chicago and Rabat, Morocco, found that a novel finger-prick test for infection with the parasite Toxoplasma gondii during pregnancy—and many other potential applications—is 100 percent sensitive ...

Scientists identify nearly 200 potential tuberculosis drug targets

August 16, 2018
Tuberculosis is one of the top 10 causes of death worldwide. Nearly 2 million people die every year from this infectious disease, and an estimated 2 billion people are chronically infected. The only vaccine, developed almost ...

First mouse model to mimic lung disease could speed discovery of more effective treatments

August 16, 2018
The biggest hurdle to finding effective therapies for idiopathic pulmonary fibrosis (IPF) – a life-threatening condition in which the lungs become scarred and breathing is increasingly difficult – has been the inability ...

Anticancer drug offers potential alternative to transplant for patients with liver failure

August 15, 2018
Patients suffering sudden liver failure could in the future benefit from a new treatment that could reduce the need for transplants, research published today shows.

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.